🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

CSPC ZhongQi Pharmaceutical Technology clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and Japan registers with CSPC ZhongQi Pharmaceutical Technology as lead sponsor. Synced 27 Sep 2026
22Current trials
16Recruiting now
24Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

CSPC ZhongQi Pharmaceutical Technology is the lead sponsor of 22 current clinical trials in our China and Japan registers. 16 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Sirolimus, Docetaxel and Ammoxetine hydrochloride enteric. The most-studied condition is Healthy Participants.

ClinicalTrials.gov trials by status

  • Recruiting1673%
  • Not yet open418%
  • Active, closed29%

Trials by phase

  • Phase 1732%
  • Phase 2523%
  • Phase 3418%
  • Phase 1/2314%
  • Phase 2/329%
  • Observational15%
01

Clinical trials sponsored by CSPC ZhongQi Pharmaceutical Technology

22 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study of CM310 in Subjects With Moderate to Severe Asthma
NCT05761028 · ClinicalTrials.gov ↗ · Moderate to Severe Asthma
Phase 2/3 Recruiting 2023-04 China, Japan
A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07418736 · ClinicalTrials.gov ↗ · Chronic Obstructive Pulmonary Disease
Phase 2 Recruiting 2025-12 China, Japan
Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
NCT06947291 · ClinicalTrials.gov ↗ · Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
Phase 2 Recruiting 2025-06 China
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and Normal Liver Function
NCT07694843 · ClinicalTrials.gov ↗ · Healthy Participants, Participants With Mild Hepatic Impairment, Participants With Moderate Hepatic Impairment
Phase 1 Recruiting 2026-03 China
Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases
NCT07117435 · ClinicalTrials.gov ↗ · Colorectal Liver Metastases, First-line Treatment
Phase 1 Recruiting 2025-05 China
A Phase I Clinical Trial to Evaluate the Pharmacokinetic Characteristics of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Moderate Renal Impairment and Normal Renal Function
NCT07694869 · ClinicalTrials.gov ↗ · Healthy Participants, Participants With Moderate Renal Impairment
Phase 1 Recruiting 2026-05 China
A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
NCT06296706 · ClinicalTrials.gov ↗ · Gastric Cancer
Phase 3 Recruiting 2024-02 China
A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors
NCT07241936 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Phase 1/2 Recruiting 2025-11 China
A Clinical Study of Paclitaxel Cationic Liposomes for the Treatment of Patients With Advanced Solid Tumors
NCT06632574 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 1 Recruiting 2014-03 China
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
NCT07165886 · ClinicalTrials.gov ↗ · Gastroenteropancreatic Neuroendocrine Tumors
Phase 2/3 Recruiting 2025-08 China
A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)
NCT06505395 · ClinicalTrials.gov ↗ · Gastrointestinal Neuroendocrine Pancreatic Tumor
Phase 2 Recruiting 2024-07 China
A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis
NCT06688435 · ClinicalTrials.gov ↗ · Myasthenia Gravis
Drug: SYS6020
Phase 1 Recruiting 2025-03 China
SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT05445154 · ClinicalTrials.gov ↗ · Newly Diagnosed Acute Myeloid Leukemia (AML)
Phase 1/2 Recruiting 2021-08 China
Evaluation of Bioequivalence and Food Effect of a New Strength Formulation of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Participants.
NCT07756996 · ClinicalTrials.gov ↗ · Healthy Participants
Phase 1 Recruiting 2026-07 China
A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085
NCT07412353 · ClinicalTrials.gov ↗ · Healthy Participants
Phase 1 Recruiting 2026-01 China
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
NCT06313086 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer
Phase 3 Recruiting 2024-03 China
A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma
NCT07684287 · ClinicalTrials.gov ↗ · Epithelioid Hemangioendothelioma
Drug: Sirolimus
Phase 2 Not yet open 2026-08 China, Japan
Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors
NCT06929325 · ClinicalTrials.gov ↗ · HR+/HER2- Advanced/Metastatic Breast Cancer
Phase 3 Not yet open 2025-04 China
SYH2095 for Advanced Malignant Tumors: Phase I Study
NCT07692776 · ClinicalTrials.gov ↗ · Advanced Malignant Tumors
Observational Not yet open 2026-07 China
A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.
NCT06136988 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable Esophageal Squamous Carcinoma
Phase 1/2 Not yet open 2023-12 China
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL
NCT04668690 · ClinicalTrials.gov ↗ · Peripheral T Cell Lymphoma
Phase 3 Active, closed 2021-04 China
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
NCT06957379 · ClinicalTrials.gov ↗ · HR+/HER2- Advanced/Metastatic Breast Cancer
Phase 2 Active, closed 2024-02 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in CSPC ZhongQi Pharmaceutical Technology trials

24 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in CSPC ZhongQi Pharmaceutical Technology trials

22 conditions
Healthy Participants4HR+/HER2- Advanced/Metastatic Breast Cancer2Chronic Obstructive Pulmonary Disease1Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors1Peripheral T Cell Lymphoma1Advanced Malignant Tumors1Participants With Mild Hepatic Impairment1Participants With Moderate Hepatic Impairment1Colorectal Liver Metastases1First-line Treatment1Locally Advanced Unresectable Esophageal Squamous Carcinoma1Participants With Moderate Renal Impairment1Gastric Cancer1Moderate to Severe Asthma1Epithelioid Hemangioendothelioma1Advanced Solid Tumors1Advanced Solid Tumor1Gastroenteropancreatic Neuroendocrine Tumors1Gastrointestinal Neuroendocrine Pancreatic Tumor1Myasthenia Gravis1Newly Diagnosed Acute Myeloid Leukemia (AML)1HER2-positive Breast Cancer1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China2216
Clinical trials in Japan32

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Healthy Participants

SponsorTrials
Innovent Biologics (Suzhou)4
Kymera Therapeutics2
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)2
Shenzhen Salubris Pharmaceuticals2
Shanghai Yidian Pharmaceutical Technology Development2
Centre Hospitalier Universitaire de Liege2
Tethis2
Astria Therapeutics1
Primus Pharmaceuticals1
ApexCPG1

Sponsors with the most current trials registered for this condition.

06

Questions about CSPC ZhongQi Pharmaceutical Technology trials

How many clinical trials does CSPC ZhongQi Pharmaceutical Technology sponsor?

CSPC ZhongQi Pharmaceutical Technology is the lead sponsor of 22 current trials on ClinicalTrials.gov in our China and Japan registers, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are CSPC ZhongQi Pharmaceutical Technology trials recruiting?

Yes. 16 of its 22 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is CSPC ZhongQi Pharmaceutical Technology testing?

Its current trials name 24 drugs and biologicals as interventions. The most frequent are Sirolimus (5), Docetaxel (3), Ammoxetine hydrochloride enteric (2), DP303c (2) and Fulvestrant (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.